| 李志坚 李哲 周勇安 王艳 王伟锋 张天翼.奈达铂或顺铂联合依托泊苷治疗小细胞肺癌的临床研究[J].,2014,14(22):4336-4338 |
| 奈达铂或顺铂联合依托泊苷治疗小细胞肺癌的临床研究 |
| Clinical Research on the Nedaplatin/Etoposide Versus Cisplatin/Etoposidein the Treatment of Small Cell Lung Cancer |
| |
| DOI： |
| 中文关键词: 奈达铂 依托泊苷 小细胞肺癌 临床疗效 安全性 |
| 英文关键词: Nedaplatin Etoposide Small-cell lung cancer Clinical efficacy Safety |
| 基金项目: |
|
| 摘要点击次数: 1007 |
| 全文下载次数: 3015 |
| 中文摘要: |
| 目的：比较奈达铂和顺铂联合依托泊苷治疗小细胞肺癌(SCLC)的近期疗效和安全性。方法：选择2012 年5 月至2013 年8
月在我院确诊为小细胞肺癌的59 例患者为研究对象，将其随机分为两组。奈达铂组给予奈达铂80 mg/m2静滴，d1；依托泊苷100
mg/m2静滴，d1；3 周为1 周期。顺铂组给予顺铂25 mg/m2静滴，d1～3；依托泊苷剂量及用法同奈达铂组。参照RECIST 1.0 和
NCI 3.0 标准评价和比较两组的近期疗效和不良反应的发生情况。结果：奈达铂组的客观有效率为51.6％，顺铂组为46.4％，两组
比较差异无统计学意义(P=0.691)。奈达铂组与顺铂组血小板、白细胞降低及贫血的发生率比较差异无统计学意义(P>0.05)，但奈
达铂组胃肠道反应及肾功能异常的发生率明显低于顺铂组，差异有统计学意义(P<0.05)。结论：奈达铂联合依托泊苷治疗小细胞
肺癌的疗效与顺铂联合依托泊苷相当，但其胃肠道反应和肾毒性的更少，安全性更高。 |
| 英文摘要: |
| Objective:To compare the clinical efficacy and safety of nedaplatin plus etoposide with cisplatin plus etoposide in the
treatment of small cell lung cancer (SCLC).Methods:59 patients who were diagnosed as SCLC from May 2012 to August 2013 in our
hospital were chosen and divided randomly into two groups for the study. The nedaplatin group was treated by nedaplatin 80mg/m2
infusion, d1; etoposide 100 mg/m2 infusion d1, 3 weeks per cycle; whilw the cisplatin group was treated by cisplatin 25 mg/m2 infusion
d1-3, etoposide 100 mg/m2 infusion d1, 3 weeks per cycle. Referring to RECIST 1.0 criteria and NCI 3.0, the efficacy and incidence of
adverse reactions were evaluated and compared between two groups.Results:The RR of nedaplatin group and cisplatin group were
51.6% and 46.4% respectively (P>0.05). No significant difference was found in the incidence rates of anemia leucopenia
thrombocytopenia between the two groups (P>0.05). The incidence rates of impaired renal function and nausea in nedaplatin group were
significantly lower than those of the cisplatin group (P<0.05).Conclusion:The clinical efficacy of edaplatin plus etoposide was equal to
cisplatin plus etoposide in the treatment of SCLC, but edaplatin plus etoposide had higer safty. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
